Description
Most of the antibiotics now in use have been discovered more or less by chance, and their mechanisms of action have only been elucidated after their discovery. To meet the medical need for next-generation antibiotics, a more rational approach to antibiotic development is clearly needed.
Opening with a general introduction about antimicrobial drugs, their targets and the problem of antibiotic resistance, this reference systematically covers currently known antibiotic classes, their molecular mechanisms and the targets on which they act. Novel targets such as cell signaling networks, riboswitches and bacterial chaperones are covered here, alongside the latest information on the molecular mechanisms of current blockbuster antibiotics.
With its broad overview of current and future antibacterial drug development, this unique reference is essential reading for anyone involved in the development and therapeutic application of novel antibiotics.
Chapter
Chapter 3 Impact of Microbial Natural Products on Antibacterial Drug Discovery
pp.:
49 – 79
Chapter 4 Antibiotics and Resistance: A Fatal Attraction
pp.:
79 – 99
Chapter 5 Fitness Costs of Antibiotic Resistance
pp.:
99 – 135
Chapter 6 Inhibitors of Cell-Wall Synthesis
pp.:
135 – 159
Chapter 7 Inhibitors of Bacterial Cell Partitioning
pp.:
159 – 177
Chapter 8 The Membrane as a Novel Target Site for Antibiotics to Kill Persisting Bacterial Pathogens
pp.:
177 – 209
Chapter 9 Bacterial Membrane, a Key for Controlling Drug Influx and Efflux
pp.:
209 – 243
Chapter 10 Interference with Bacterial Cell-to-Cell Chemical Signaling in Development of New Anti-Infectives
pp.:
243 – 267
Chapter 11 Recent Developments in Inhibitors of Bacterial Type IIA Topoisomerases
pp.:
267 – 289
Chapter 12 Antibiotics Targeting Bacterial RNA Polymerase
pp.:
289 – 325
Chapter 13 Inhibitors Targeting Riboswitches and Ribozymes
pp.:
325 – 349
Chapter 14 Targeting Ribonuclease P
pp.:
349 – 381
Chapter 15 Involvement of Ribosome Biogenesis in Antibiotic Function, Acquired Resistance, and Future Opportunities in Drug Discovery
pp.:
381 – 397
Chapter 16 Aminoacyl-tRNA Synthetase Inhibitors
pp.:
397 – 413
Chapter 17 Antibiotics Targeting Translation Initiation in Prokaryotes
pp.:
413 – 437
Chapter 18 Inhibitors of Bacterial Elongation Factor EF-Tu
pp.:
437 – 463
Chapter 19 Aminoglycoside Antibiotics: Structural Decoding of Inhibitors Targeting the Ribosomal Decoding A Site
pp.:
463 – 479
Chapter 20 Peptidyltransferase Inhibitors of the Bacterial Ribosome
pp.:
479 – 497
Chapter 21 Antibiotics Inhibiting the Translocation Step of Protein Elongation on the Ribosome
pp.:
497 – 517
Chapter 22 Antibiotics at the Ribosomal Exit Tunnel-Selected Structural Aspects
pp.:
517 – 535
Chapter 23 Targeting HSP70 to Fight Cancer and Bad Bugs: One and the Same Battle?
pp.:
535 – 551